as 11-15-2024 4:00pm EST
Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
Founded: | 1887 | Country: | Ireland |
Employees: | N/A | City: | DUBLIN 2 |
Market Cap: | 3.6B | IPO Year: | 1991 |
Target Price: | $37.00 | AVG Volume (30 days): | 1.9M |
Analyst Decision: | Buy | Number of Analysts: | 4 |
Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
EPS: | -1.17 | EPS Growth: | N/A |
52 Week Low/High: | $23.89 - $34.60 | Next Earning Date: | 11-06-2024 |
Revenue: | $4,392,000,000 | Revenue Growth: | -5.63% |
Revenue Growth (this year): | -2.81% | Revenue Growth (next year): | 4.51% |
Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Doyle Katherine C. | PRGO | Director | Sep 13 '24 | Sell | $27.30 | 8,954 | $244,444.20 | 6,009 | |
Janish Ronald Craig | PRGO | EVP, Gbl Ops & SC & CTO | Aug 26 '24 | Sell | $29.40 | 13,000 | $382,245.50 | 20,553 | |
Andersen Svend | PRGO | EVP & President CHCI | Aug 20 '24 | Sell | $27.58 | 34,983 | $968,560.28 | 81,353 |
PRGO Breaking Stock News: Dive into PRGO Ticker-Specific Updates for Smart Investing
Zacks
6 days ago
Simply Wall St.
9 days ago
Simply Wall St.
10 days ago
GuruFocus.com
11 days ago
Morningstar Research
11 days ago
Zacks
11 days ago
PR Newswire
11 days ago
Zacks
11 days ago
The information presented on this page, "PRGO Perrigo Company plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.